Shots:
- Roche has reported the P-III (CELESTIMO) trial assessing Lunsumio (mosunetuzumab) + lenalidomide vs MabThera + lenalidomide in pts with r/r follicular lymphoma who have received ≥1L of prior systemic therapy
- Trial met its 1EP, showing a statistically significant & clinically meaningful improvement in PFS, while OS data remained immature at the interim analysis; the results will be submitted to health authorities & presented at an upcoming meeting
- The FDA accepted the sBLA for Lunsumio + Polivy in 2L+ DLBCL based on SUNMO data, while CELESTIMO supports continued expansion of Lunsumio + lenalidomide in earlier FL treatment, with the P-III (MorningLyte) study ongoing in first-line FL
Ref: Globenewswire | Image: Roche | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
